Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Glucodynamics of LY3192767 in Healthy Subjects
NCT03025009Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3192767 in diabetes mellitus (DM) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s). Started Mar 2017; status: completed.
02
Drugs
LY3192767
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03025009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03025009.